Cohance Lifesciences completed its merger, expanding its CRDMO platform.

This year, revenue hit ₹2,269 Cr, Adjusted EBITDA ₹477 Cr, and net cash ₹153 Cr.

Expect continued growth from new commercial orders, especially in ADC/Oligo.

Nacharam facility received a US FDA Warning Letter; minor filing delay also noted.